Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.

The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies.

Data from the phase 3 MK-3475A-D77 trial support the Japanese approval of subcutaneous pembrolizumab and berahyaluronidase alfa.

The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.

The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.

The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed/refractory multiple myeloma.

C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.